शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:PANACEABIO

PANACEA BIOTEC LTD

Healthcare › Pharmaceuticals & Biotechnology
₹343.90
at close · 6 Nov 2026
▼ 11.75 (-3.30%)

Latest filings

Next results: Sat, 14 Nov · Financial Results
  1. Board meeting to approve results for quarter and half-year ended September 2026 · Results
  2. Newspaper notice on special window for physical share dematerialisation · Compliance
  3. Routine compliance certificate on share dematerialisation for Q2 FY27 · Compliance
All filings ↓
Ask Nexa about PANACEA BIOTEC LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹673 Cr over the trailing twelve months.

Market Cap
₹2,180 Cr
P / E (TTM)
—
EV / EBITDA
980.1×
Div Yield
—
Growth
0.5%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
0.5%·
ROCE (5y median)
ROE -0.9% (5y median) · margin -0.7%
Leverage
0.03·
Debt / Equity · low
Net cash ₹34 Cr
Revenue FY21→FY26
1.0×▲
Margin +22.5 pts
₹625 Cr → ₹640 Cr
Cash conversion
-0.53×▼
Operating cash ÷ profit · 5 yrs
₹-543 Cr on ₹1,027 Cr
Moves on a normal day
1.80%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#72/163
ROCE#151/177
ROE#146/165
Debt / Equity#57/166
EBITDA margin#143/179
Revenue growth#70/162
Profit growth#131/157

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Debt at 0.03× equity
lower than 66% of its 166 Pharmaceuticals peers
Concerns
Slow revenue growth — 1% a year over 5 years
Returns on capital 0.5% (5-year median)
#151 of 177 in Pharmaceuticals on the latest reported figures · down from 5.4% in FY21
Over 5 years it reported ₹1,027 Cr of profit and an operating cash outflow of ₹543 Cr — -0.53×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from PANACEA BIOTEC LTD's filed financials and exchange disclosures

What does PANACEA BIOTEC LTD do?

PANACEA BIOTEC LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PANACEABIO.

Is PANACEA BIOTEC LTD profitable?

No. Over the trailing twelve months PANACEA BIOTEC LTD reported a net loss of ₹8.92 Cr on revenue of ₹673 Cr.

Does PANACEA BIOTEC LTD pay a dividend?

Not in the latest reported year — PANACEA BIOTEC LTD's dividend payout for FY26 was nil.

Is PANACEA BIOTEC LTD debt-free?

On a net basis, yes. It reported borrowings of ₹24 Cr on its 31 Mar 2026 balance sheet, but holds ₹34 Cr more cash than debt.

How much does the PANACEA BIOTEC LTD share price move in a day?

On a typical session PANACEA BIOTEC LTD moves 1.80% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

When are PANACEA BIOTEC LTD's next results?

Financial Results on Sat, 14 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track PANACEA BIOTEC LTD's announcements?

Every NSE and BSE filing by PANACEA BIOTEC LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.